Akeso Initiates Phase 3 Trial for Ivonescimab vs. Tislelizumab in First-line Squamous NSCLC Treatment
Akeso has announced the initiation of a pivotal phase III trial for ivonescimab, an investigational PD-1/VEGF bi-specific antibody, with the dosing of its first patient. This bi-specific antibody is simultaneously targeting PD-1 and VEGF pathways.
Ivonescimab, designated as AK112 by Akeso in China and Australia, and as SMT112 by Summit in the United States, Canada, Europe, and Japan uniquely integrates the benefits of PD-1 immunotherapy blockade and VEGF anti-angiogenesis inhibition into a singular molecule. Currently, ivonescimab is actively undergoing multiple Phase III clinical trials across the globe.
The Phase III trial will focus on evaluating both the clinical effectiveness and safety profile of ivonescimab when compared to tislelizumab, combined with chemotherapy, as the initial treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).
Ivonescimab is concurrently being assessed through various Phase III head-to-head trials against established PD-(L)1 inhibitors for lung cancer treatment. These trials span multiple developed countries worldwide, encompassing China, the United States, Europe, and other prominent regions.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!